Do analysts recommend CODX or VBIO?

Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 8,729.30%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Co-Diagnostics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor CODX or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.69 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that Co-Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Co-Diagnostics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate VBIO or APRE?

Aprea Therapeutics has a consensus target price of $2.80, indicating a potential upside of 380.27%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is VBIO or APRE more profitable?

Aprea Therapeutics' return on equity of -47.60% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Valion Bio, Inc. Common Stock N/A -193.17% -67.10% Aprea Therapeutics N/A -47.60% -40.97%

Does the media refer more to VBIO or APRE?

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.93 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valion Bio, Inc. Common Stock 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRSN or VBIO more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets NeuroSense Therapeutics N/A N/A N/A Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Does the media favor NRSN or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 5 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.43 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend MTVA or VBIO?

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 1,370.59%. Given MetaVia's stronger consensus rating and higher possible upside, equities research analysts plainly believe MetaVia is more favorable than Valion Bio, Inc. Common Stock. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MTVA or VBIO more profitable?

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -209.67% -107.91% Valion Bio, Inc. Common Stock N/A -193.17% -67.10%

Does the media prefer MTVA or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than MetaVia. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 5 mentions for MetaVia. MetaVia's average media sentiment score of 0.75 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that MetaVia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MetaVia 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Valion Bio, Inc. Common Stock 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer OSRH or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer OSRH or VBIO?

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than OSR. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 2 mentions for OSR. Valion Bio, Inc. Common Stock's average media sentiment score of 0.40 beat OSR's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OSR 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Valion Bio, Inc. Common Stock (VBIO) Competitors

$1.45 -0.10 (-6.45%)

As of 10/14/2026 04:00 PM Eastern

Compare

VBIO vs. CODX, APRE, NRSN, MTVA, and OSRH

Should you buy Valion Bio, Inc. Common Stock stock or one of its competitors? Valion Bio, Inc. Common Stock's main competitors and comparable companies include Co-Diagnostics (CODX), Aprea Therapeutics (APRE), NeuroSense Therapeutics (NRSN), MetaVia (MTVA), and OSR (OSRH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Valion Bio, Inc. Common Stock compare to Co-Diagnostics?

Co-Diagnostics (NASDAQ:CODX) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Co-Diagnostics presently has a consensus target price of $67.50, indicating a potential upside of 8,729.30%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Co-Diagnostics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Co-Diagnostics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Co-Diagnostics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Co-Diagnostics. Co-Diagnostics' average media sentiment score of 0.69 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that Co-Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Co-Diagnostics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 2.3% of Co-Diagnostics shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valion Bio, Inc. Common Stock has higher revenue and earnings than Co-Diagnostics. Co-Diagnostics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Co-Diagnostics	$620K	8.61	-$46.90M	-$10.32	N/A
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$159.25	N/A

Co-Diagnostics has a beta of 2.9, meaning that its stock price is 190% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to Co-Diagnostics' net margin of -6,531.77%. Valion Bio, Inc. Common Stock's return on equity of -193.17% beat Co-Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Co-Diagnostics	-6,531.77%	-210.99%	-174.97%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Summary

Co-Diagnostics beats Valion Bio, Inc. Common Stock on 9 of the 17 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $2.80, indicating a potential upside of 380.27%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Valion Bio, Inc. Common Stock had 3 more articles in the media than Aprea Therapeutics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 3 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.93 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valion Bio, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Valion Bio, Inc. Common Stock has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$159.25	N/A
Aprea Therapeutics	$290K	25.31	-$12.60M	-$1.08	N/A

Aprea Therapeutics' return on equity of -47.60% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
Aprea Therapeutics	N/A	-47.60%	-40.97%

4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aprea Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

NeuroSense Therapeutics currently has a consensus price target of $170.00, indicating a potential upside of 5,455.56%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeuroSense Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

NeuroSense Therapeutics' return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Valion Bio, Inc. Common Stock has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$10.80	N/A
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$159.25	N/A

NeuroSense Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, suggesting that its share price is 80% more volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 5 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.43 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

NeuroSense Therapeutics beats Valion Bio, Inc. Common Stock on 8 of the 14 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

Valion Bio, Inc. Common Stock has higher revenue and earnings than MetaVia. MetaVia is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$3.23	N/A
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$159.25	N/A

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 0.6% of MetaVia shares are owned by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valion Bio, Inc. Common Stock's return on equity of -193.17% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-209.67%	-107.91%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

MetaVia currently has a consensus target price of $20.00, suggesting a potential upside of 1,370.59%. Given MetaVia's stronger consensus rating and higher possible upside, equities research analysts plainly believe MetaVia is more favorable than Valion Bio, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

MetaVia has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 1 more articles in the media than MetaVia. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 5 mentions for MetaVia. MetaVia's average media sentiment score of 0.75 beat Valion Bio, Inc. Common Stock's score of 0.40 indicating that MetaVia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MetaVia	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Valion Bio, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Valion Bio, Inc. Common Stock beats MetaVia on 8 of the 13 factors compared between the two stocks.

How does Valion Bio, Inc. Common Stock compare to OSR?

OSR (NASDAQ:OSRH) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Valion Bio, Inc. Common Stock has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	3.89	-$27.06M	-$0.37	N/A
Valion Bio, Inc. Common Stock	$780K	1.65	-$8.88M	-$159.25	N/A

OSR has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

In the previous week, Valion Bio, Inc. Common Stock had 4 more articles in the media than OSR. MarketBeat recorded 6 mentions for Valion Bio, Inc. Common Stock and 2 mentions for OSR. Valion Bio, Inc. Common Stock's average media sentiment score of 0.40 beat OSR's score of 0.00 indicating that Valion Bio, Inc. Common Stock is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OSR	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

55.3% of OSR shares are held by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are held by institutional investors. 36.9% of OSR shares are held by company insiders. Comparatively, 2.5% of Valion Bio, Inc. Common Stock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valion Bio, Inc. Common Stock has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%

Summary

OSR beats Valion Bio, Inc. Common Stock on 7 of the 13 factors compared between the two stocks.

Get Valion Bio, Inc. Common Stock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VBIO vs. The Competition

Export

Metric	Valion Bio, Inc. Common Stock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.38M	$3.84B	$7.18B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	-0.01	9.86	213.76	19.47
Price / Sales	1.65	1,170.93	573.62	81.29
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	0.01	16.02	10.29	5.92
Net Income	-$8.88M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-34.39%	-5.88%	-3.54%	-3.85%
1 Month Performance	-31.28%	-12.92%	-7.80%	-6.37%
1 Year Performance	-98.06%	2.99%	0.77%	-6.01%

Valion Bio, Inc. Common Stock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VBIO Valion Bio, Inc. Common Stock	0.3321 of 5 stars	$1.45 -6.5%	N/A	-98.1%	$1.38M	$780K	N/A	10	News Coverage Short Interest Increase
CODX Co-Diagnostics	2.2374 of 5 stars	$1.12 -2.6%	$67.50 +5,926.8%	-93.2%	$8.03M	$620K	N/A	115
APRE Aprea Therapeutics	3.8871 of 5 stars	$0.61 -4.8%	$3.07 +406.9%	-61.4%	$8M	$290K	N/A	8	News Coverage Analyst Forecast
NRSN NeuroSense Therapeutics	2.7494 of 5 stars	$3.82 -6.1%	$170.00 +4,350.3%	-87.6%	$7.72M	N/A	N/A	16	Analyst Downgrade Gap Down
MTVA MetaVia	2.6678 of 5 stars	$1.46 -1.4%	$20.00 +1,269.9%	-87.9%	$7.64M	N/A	N/A	8	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VBIO) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. CODX, APRE, NRSN, MTVA, and OSRH

How does Valion Bio, Inc. Common Stock compare to Co-Diagnostics?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to NeuroSense Therapeutics?

Summary

How does Valion Bio, Inc. Common Stock compare to MetaVia?

Summary

How does Valion Bio, Inc. Common Stock compare to OSR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valion Bio, Inc. Common Stock (VBIO) Competitors

VBIO vs. CODX, APRE, NRSN, MTVA, and OSRH

How does Valion Bio, Inc. Common Stock compare to Co-Diagnostics?

Do analysts recommend CODX or VBIO?

Does the media favor CODX or VBIO?

Do insiders & institutionals believe in CODX or VBIO?

Which has higher valuation and earnings, CODX or VBIO?

Which has more risk & volatility, CODX or VBIO?

Is CODX or VBIO more profitable?

Summary

How does Valion Bio, Inc. Common Stock compare to Aprea Therapeutics?

Which has more risk & volatility, VBIO or APRE?

Do analysts rate VBIO or APRE?

Does the media refer more to VBIO or APRE?

Which has stronger earnings & valuation, VBIO or APRE?

Is VBIO or APRE more profitable?

Do institutionals & insiders hold more shares of VBIO or APRE?

Summary

How does Valion Bio, Inc. Common Stock compare to NeuroSense Therapeutics?

Do insiders & institutionals believe in NRSN or VBIO?

Do analysts prefer NRSN or VBIO?

Is NRSN or VBIO more profitable?

Which has stronger earnings and valuation, NRSN or VBIO?

Which has more risk and volatility, NRSN or VBIO?

Does the media favor NRSN or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to MetaVia?

Which has stronger earnings & valuation, MTVA or VBIO?

Do insiders & institutionals hold more shares of MTVA or VBIO?

Is MTVA or VBIO more profitable?

Do analysts recommend MTVA or VBIO?

Which has more risk & volatility, MTVA or VBIO?

Does the media prefer MTVA or VBIO?

Summary

How does Valion Bio, Inc. Common Stock compare to OSR?

Do analysts prefer OSRH or VBIO?

Which has preferable valuation and earnings, OSRH or VBIO?

Which has more risk & volatility, OSRH or VBIO?

Does the media prefer OSRH or VBIO?

Do insiders and institutionals believe in OSRH or VBIO?

Is OSRH or VBIO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VBIO vs. The Competition

Valion Bio, Inc. Common Stock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools